139 related articles for article (PubMed ID: 7705802)
1. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid.
Durand F; Bernuau J; Pessayre D; Samuel D; Belaiche J; Degott C; Bismuth H; Belghiti J; Erlinger S; Rueff B
Hepatology; 1995 Apr; 21(4):929-32. PubMed ID: 7705802
[TBL] [Abstract][Full Text] [Related]
2. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy.
Idilman R; Ersoz S; Coban S; Kumbasar O; Bozkaya H
Liver Transpl; 2006 Sep; 12(9):1427-30. PubMed ID: 16933231
[TBL] [Abstract][Full Text] [Related]
3. [Fulminant hepatitis during the therapy for tuberculous meningitis].
Garavelli PL
Recenti Prog Med; 1996 Dec; 87(12):597. PubMed ID: 9102699
[No Abstract] [Full Text] [Related]
4. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
[TBL] [Abstract][Full Text] [Related]
5. [Case of fatal liver failure due to anti-tuberculous therapy].
Harada Y; Kawakami K; Koyama K; Yamaryo T; Kimura Y
Kekkaku; 2007 Sep; 82(9):705-9. PubMed ID: 17969987
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
8. Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure.
Miwa S; Hashikura Y; Mita A; Kubota T; Chisuwa H; Nakazawa Y; Ikegami T; Terada M; Miyagawa S; Kawasaki S
Hepatology; 1999 Dec; 30(6):1521-6. PubMed ID: 10573533
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
11. Anti-tuberculous therapy and acute liver failure.
Mitchell I; Wendon J; Fitt S; Williams R
Lancet; 1995 Mar; 345(8949):555-6. PubMed ID: 7786350
[TBL] [Abstract][Full Text] [Related]
12. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
13. [Fulminant and subfulminant viral hepatitis].
Bernuau J
Rev Prat; 1990 Jun; 40(18):1652-5. PubMed ID: 2371517
[TBL] [Abstract][Full Text] [Related]
14. [Adverse effects related to the use of antitubercular drugs in psychiatric centers: retrospective study at the Philippe Pinel CH in Amiens 1994].
Decocq G; Compagnon M; Andréjak M; Guedj B; Doutrellot C
Therapie; 1996; 51(5):543-9. PubMed ID: 9138390
[TBL] [Abstract][Full Text] [Related]
15. [Fulminant, rapidly reversible hepatitis and life-threatening anaphylaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency].
Canova CR; Kuhn M; Zellweger U; Reinhart WH
Schweiz Med Wochenschr; 1996 Mar; 126(10):392-7. PubMed ID: 8643939
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of complete and split liver grafts for patients with fulminant hepatic failure.
Sterneck M; Fischer L; Buggisch P; Malago M; Rogiers X; Burdelski M; Greten H; Broelsch CE
Z Gastroenterol; 1996 Dec; 34(12):795-800. PubMed ID: 9017895
[TBL] [Abstract][Full Text] [Related]
18. Antituberculous therapy and acute liver failure.
Durand F; Pessayre D; Fournier M; Belghiti J; Erlinger S; Bernuau J
Lancet; 1995 May; 345(8958):1170. PubMed ID: 7723555
[No Abstract] [Full Text] [Related]
19. Prognostic assessment of fulminant hepatitis from indication criteria for liver transplantation.
Watanabe A; Shiota T; Tsuji T
J Med; 1992; 23(1):39-49. PubMed ID: 1374114
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.
Farrell FJ; Keeffe EB; Man KM; Imperial JC; Esquivel CO
Dig Dis Sci; 1994 Oct; 39(10):2255-9. PubMed ID: 7924752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
